← Back to Search

Targeted Therapy

A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 11
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing how a stomach acid-reducing medication and an acidic drink affect the way a drug is processed in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 11
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 11 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Omeprazole + SotorasibExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Omeprazole
2006
Completed Phase 4
~940
Sotorasib
2021
Completed Phase 1
~370

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AmgenLead Sponsor
1,442 Previous Clinical Trials
1,397,728 Total Patients Enrolled
MDStudy DirectorAmgen
980 Previous Clinical Trials
941,484 Total Patients Enrolled
~5 spots leftby Dec 2025